LabGenomics Co. Ltd
LabGenomics Co., Ltd. engages in the research and development of biotechnology products in South Korea. It is also involved in the sale of diagnostic devices. The company was founded in 2002 and is based in Seongnam-si, South Korea.
LabGenomics Co. Ltd (084650) - Total Liabilities
Latest total liabilities as of September 2025: ₩76.00 Billion KRW
Based on the latest financial reports, LabGenomics Co. Ltd (084650) has total liabilities worth ₩76.00 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LabGenomics Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how LabGenomics Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LabGenomics Co. Ltd Competitors by Total Liabilities
The table below lists competitors of LabGenomics Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Iofina plc
PINK:IOFNF
|
USA | $19.91 Million |
|
Grand River Commerce Inc
OTCQX:GNRV
|
USA | $476.83 Million |
|
HNO International Inc
PINK:HNOI
|
USA | $3.36 Million |
|
Beijing JIAYU Door Window Curtain
SHE:300117
|
China | CN¥2.84 Billion |
|
Hiroca Holdings Ltd
TW:1338
|
Taiwan | NT$4.27 Billion |
|
New Delhi Television Limited
NSE:NDTV
|
India | ₹7.78 Billion |
|
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
|
USA | $422.81K |
|
TJ media Co. Ltd
KQ:032540
|
Korea | ₩42.02 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down LabGenomics Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LabGenomics Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LabGenomics Co. Ltd (2014–2024)
The table below shows the annual total liabilities of LabGenomics Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩79.35 Billion | -6.99% |
| 2023-12-31 | ₩85.31 Billion | +106.46% |
| 2022-12-31 | ₩41.32 Billion | -11.27% |
| 2021-12-31 | ₩46.57 Billion | +67.40% |
| 2020-12-31 | ₩27.82 Billion | +45.96% |
| 2019-12-31 | ₩19.06 Billion | +12.17% |
| 2018-12-31 | ₩16.99 Billion | -3.02% |
| 2017-12-31 | ₩17.52 Billion | -3.59% |
| 2016-12-31 | ₩18.17 Billion | +90.55% |
| 2015-12-31 | ₩9.54 Billion | -3.26% |
| 2014-12-31 | ₩9.86 Billion | -- |